

FEES TRANSMITTAL

Patent fees are subject to annual revision.

FINAL AMOUNT OF PAYMENT

\$180

<i>Complete if Known</i>	
Application Number	10/010,678
Filing Date	December 7, 2001
First Named Inventor	G.J. GORMLEY et al.
Examiner Name	V.Y. Kim
Group Art Unit	1614
Attorney Docket Number	19109DE

METHOD OF PAYMENT (Check one)

Deposit Account

Deposit Account
Number

13-2755

**Deposit Account
Name**

Merck & Co., Inc.

The Commissioner is authorized to:

Charge fee(s) indicated below Credit any overpayments

Charge any additional fee(s) during the pendency of this application

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Fee Code	Large Entity Fee (\$)	Fee Description	Fee Paid
1051	130	Surcharge - late filing fee or oath	
1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1251	110	Extension for reply within first month	
1252	400	Extension for reply within second month	
1253	920	Extension for reply within third month	
1254	1,440	Extension for reply within fourth month	
1255	1,960	Extension for reply within fifth month	
1401	320	Notice of Appeal	
1402	320	Filing a brief in support of an appeal	
1403	280	Request for oral hearing	
1452	110	Petition to revive - unavoidable	
1453	1,280	Petition to revive - unintentional	
1501	1,280	Utility issue fee (or reissue)	
1502	460	Design issue fee	
1460	130	Petitions to the Commissioner	
1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	Submission of Information Disclosure Statement	180
8021	40	Recording each patent assignment per property (times number of properties)	
1809	740	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	740	For each additional invention to be examined (37 CFR 1.129(b))	
1801	740	Request for Continued Examination (RCE)	

TECH CENTER 1600/2900

NOV 01 2002

FEE CALCULATION

1. BASIC FILING FEE

Large Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
1001	740	Utility filing fee	
1002	330	Design filing fee	
1004	740	Reissue filing fee	
1005	160	Provisional filing fee	
SUBTOTAL(1)			\$0

2. EXTRA CLAIM FEES

			Extra Fee from below	Fee Paid
Total Claims	<input type="text"/>	- 20	** = 0	x \$18 = 0
Independent Claims	<input type="text"/>	- 3	** = 0	x \$84 = 0
Multiple Dependent Claims				\$280 =

****or number previously paid, if greater; For Reissues, see below**

Large Fee Code	Entity Fee (\$)	Fee Description
1202	18	Claims in excess of 20
1201	84	Independent claims in excess of 3
1203	280	Multiple dependent claim, if not paid
1204	84	**Reissue independent claims over original patent
1205	18	**Reissue claims in excess of 20 and over original patent
SUBTOTAL(2)		
		\$0

SUBMITTED BY			Complete (if applicable)	
Typed or Printed Name	CATHERINE D. FITCH			Reg. Number 36,502
Signature			Date 10/25/2002	Deposit Account User ID

Application Number: 10/010,678
Filing Date: OCT 30 2002 12/07/2001
First Named Inventor: G.J. GORMLEY et al.
Group Art Unit: 1614
Examiner Name: V.Y. Kim
Attorney Docket Number: 19109DE


FIRST CLASS MAIL CERTIFICATE

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON THE DATE APPEARING BELOW.

MERCK & CO., INC.

MAILED BY Catherine Dorn DATE 10/25/2002

RECEIVED
NOV 01 2002
TECH CENTER 1600/2900



Applicants: G.J. GORMLEY et al.

Serial No. 10/010,678

Filed: December 7, 2001

For: TRANSDERMAL TREATMENT WITH
5-ALPHA REDUCTASE INHIBITORS (as
amended)Assistant Commissioner for Patents
Washington, D.C. 20231

Art Unit: 1614

Examiner: V.Y. Kim

TECH CENTER 1600/2900
NOV 01 2002RECEIVED
11/6/02

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97**

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

10/31/2002 MAHMED1 00000002 132755 10010678
01 FC:1806 180.00 CH

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

By *Catherine D'Ach* Date 10/25/02



INFORMATION DISCLOSURE STATEMENT

4. Except for Cite Nos. _____, copies of the references listed on the attached form are not enclosed because they have been submitted to or cited by the Office in a related application as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE
		RECEIVED
		NOV 01 2002
		TECH CENTER 1600/2900

upon which the instant application relies for an earlier filing date under 35 U.S.C. 120. Therefore, pursuant to 37 C.F.R. 1.98(d), copies of these references are not enclosed herewith. If this is inconvenient, additional copies will be submitted upon request.

5. In accordance with 37 C.F.R. 1.97, (check one)

the attached information is filed within three months of the filing date of the captioned case.

the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.

the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).

the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

Catherine D. Fitch

By: CATHERINE D. FITCH

Attorney _____ For Applicant(s)

Reg. No. 36,502

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-4283

Date: October 25, 2002